Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2015) et al.   JOURNAL OF HEPATOLOGY

Clinical Trials of Combined Molecular Targeted Therapy and Locoregional Therapy in Hepatocellular Carcinoma: Past, Present, and Future

(2014) Hwi Young Kim et al.   Liver Cancer

Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization

(2013) Riad Salem et al.   Clinical Gastroenterology and Hepatology

Long-term survival after surgical resection for huge hepatocellular carcinoma: Comparison with transarterial chemoembolization after propensity score matching

(2013) Yang Won Min et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma

(2013) Kaijun Huang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma

(2012) Myeong Jun Song et al.   JOURNAL OF HEPATOLOGY

Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)

(2012) Joong-Won Park et al.   LIVER INTERNATIONAL

Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial

(2012) D. Sansonno et al.   ONCOLOGIST

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

(2011) Masatoshi Kudo et al.   EUROPEAN JOURNAL OF CANCER

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma

(2010) Riad Salem et al.   GASTROENTEROLOGY

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Benefit of downsizing hepatocellular carcinoma in a liver transplant population

(2009) J. W. JANG et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Outcome after curative resection for a huge (≥10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification

(2009) Gi Hong Choi et al.   AMERICAN JOURNAL OF SURGERY

Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion

(2009) Kang Mo Kim et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis

(2008) Francis Y. Yao et al.   HEPATOLOGY

Chemoembolization Combined With Radiofrequency Ablation for Patients With Hepatocellular Carcinoma Larger Than 3 cm

(2008) Bao-Quan Cheng et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE